nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—ABCB1—ovarian cancer	0.25	1	CbGaD
Vismodegib—ABCG2—Topotecan—ovarian cancer	0.102	0.215	CbGbCtD
Vismodegib—ABCG2—Paclitaxel—ovarian cancer	0.0504	0.106	CbGbCtD
Vismodegib—ABCG2—Carboplatin—ovarian cancer	0.0474	0.0999	CbGbCtD
Vismodegib—ABCB1—Topotecan—ovarian cancer	0.0367	0.0773	CbGbCtD
Vismodegib—ABCG2—Docetaxel—ovarian cancer	0.0364	0.0768	CbGbCtD
Vismodegib—ABCG2—Doxorubicin—ovarian cancer	0.0271	0.0572	CbGbCtD
Vismodegib—CYP2C8—Paclitaxel—ovarian cancer	0.0268	0.0566	CbGbCtD
Vismodegib—ABCB1—Vinorelbine—ovarian cancer	0.0258	0.0545	CbGbCtD
Vismodegib—CYP3A4—Topotecan—ovarian cancer	0.022	0.0463	CbGbCtD
Vismodegib—CYP2C9—Paclitaxel—ovarian cancer	0.0187	0.0395	CbGbCtD
Vismodegib—ABCB1—Paclitaxel—ovarian cancer	0.0182	0.0383	CbGbCtD
Vismodegib—CYP3A4—Vinorelbine—ovarian cancer	0.0155	0.0327	CbGbCtD
Vismodegib—ABCB1—Docetaxel—ovarian cancer	0.0131	0.0277	CbGbCtD
Vismodegib—CYP3A4—Paclitaxel—ovarian cancer	0.0109	0.0229	CbGbCtD
Vismodegib—ABCB1—Doxorubicin—ovarian cancer	0.00979	0.0206	CbGbCtD
Vismodegib—CYP3A4—Docetaxel—ovarian cancer	0.00787	0.0166	CbGbCtD
Vismodegib—CYP3A4—Doxorubicin—ovarian cancer	0.00586	0.0124	CbGbCtD
Vismodegib—SHH—embryo—ovarian cancer	0.00554	0.0818	CbGeAlD
Vismodegib—SHH—epithelium—ovarian cancer	0.00452	0.0668	CbGeAlD
Vismodegib—SHH—endometrium—ovarian cancer	0.00405	0.0599	CbGeAlD
Vismodegib—SMO—myometrium—ovarian cancer	0.00403	0.0595	CbGeAlD
Vismodegib—SMO—embryo—ovarian cancer	0.00387	0.0572	CbGeAlD
Vismodegib—SHH—female reproductive system—ovarian cancer	0.00336	0.0496	CbGeAlD
Vismodegib—SHH—bone marrow—ovarian cancer	0.00317	0.0468	CbGeAlD
Vismodegib—SMO—uterine cervix—ovarian cancer	0.00313	0.0463	CbGeAlD
Vismodegib—SMO—endometrium—ovarian cancer	0.00284	0.0419	CbGeAlD
Vismodegib—SMO—uterus—ovarian cancer	0.00261	0.0386	CbGeAlD
Vismodegib—SMO—female reproductive system—ovarian cancer	0.00235	0.0347	CbGeAlD
Vismodegib—SMO—female gonad—ovarian cancer	0.00214	0.0316	CbGeAlD
Vismodegib—SMO—vagina—ovarian cancer	0.00212	0.0314	CbGeAlD
Vismodegib—SMO—testis—ovarian cancer	0.0019	0.028	CbGeAlD
Vismodegib—SMO—lymph node—ovarian cancer	0.00137	0.0203	CbGeAlD
Vismodegib—ORM1—endometrium—ovarian cancer	0.00124	0.0183	CbGeAlD
Vismodegib—Asthenia—Altretamine—ovarian cancer	0.00112	0.00893	CcSEcCtD
Vismodegib—Musculoskeletal chest pain—Doxorubicin—ovarian cancer	0.00109	0.00867	CcSEcCtD
Vismodegib—ABCG2—myometrium—ovarian cancer	0.00105	0.0156	CbGeAlD
Vismodegib—ORM1—female reproductive system—ovarian cancer	0.00103	0.0152	CbGeAlD
Vismodegib—Vomiting—Altretamine—ovarian cancer	0.000993	0.00791	CcSEcCtD
Vismodegib—Hyponatraemia—Melphalan—ovarian cancer	0.000988	0.00788	CcSEcCtD
Vismodegib—ORM1—bone marrow—ovarian cancer	0.000969	0.0143	CbGeAlD
Vismodegib—Nausea—Altretamine—ovarian cancer	0.000927	0.00739	CcSEcCtD
Vismodegib—Pain—Carboplatin—ovarian cancer	0.000922	0.00735	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Topotecan—ovarian cancer	0.000905	0.00722	CcSEcCtD
Vismodegib—Hyponatraemia—Vinorelbine—ovarian cancer	0.000863	0.00688	CcSEcCtD
Vismodegib—Ageusia—Docetaxel—ovarian cancer	0.000833	0.00665	CcSEcCtD
Vismodegib—ABCG2—uterine cervix—ovarian cancer	0.000821	0.0121	CbGeAlD
Vismodegib—Musculoskeletal pain—Paclitaxel—ovarian cancer	0.000806	0.00643	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Paclitaxel—ovarian cancer	0.000797	0.00635	CcSEcCtD
Vismodegib—ABCG2—decidua—ovarian cancer	0.000782	0.0116	CbGeAlD
Vismodegib—Aspartate aminotransferase increased—Vinorelbine—ovarian cancer	0.000774	0.00617	CcSEcCtD
Vismodegib—Amenorrhoea—Docetaxel—ovarian cancer	0.000768	0.00613	CcSEcCtD
Vismodegib—CYP2C8—endometrium—ovarian cancer	0.000764	0.0113	CbGeAlD
Vismodegib—ABCG2—endometrium—ovarian cancer	0.000742	0.011	CbGeAlD
Vismodegib—ALB—testis—ovarian cancer	0.000726	0.0107	CbGeAlD
Vismodegib—Alopecia—Chlorambucil—ovarian cancer	0.00069	0.0055	CcSEcCtD
Vismodegib—ABCG2—uterus—ovarian cancer	0.000684	0.0101	CbGeAlD
Vismodegib—Phosphatase alkaline increased—Docetaxel—ovarian cancer	0.000675	0.00538	CcSEcCtD
Vismodegib—Weight decreased—Vinorelbine—ovarian cancer	0.000672	0.00536	CcSEcCtD
Vismodegib—Connective tissue disorder—Melphalan—ovarian cancer	0.000669	0.00533	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Paclitaxel—ovarian cancer	0.000665	0.0053	CcSEcCtD
Vismodegib—CYP2C19—vagina—ovarian cancer	0.000655	0.00968	CbGeAlD
Vismodegib—Tolvaptan—ABCB1—ovarian cancer	0.000634	0.703	CrCbGaD
Vismodegib—CYP2C8—female reproductive system—ovarian cancer	0.000633	0.00934	CbGeAlD
Vismodegib—Alopecia—Topotecan—ovarian cancer	0.000614	0.0049	CcSEcCtD
Vismodegib—Malnutrition—Topotecan—ovarian cancer	0.000605	0.00483	CcSEcCtD
Vismodegib—Alopecia—Melphalan—ovarian cancer	0.000602	0.0048	CcSEcCtD
Vismodegib—ORM1—lymph node—ovarian cancer	0.0006	0.00887	CbGeAlD
Vismodegib—Back pain—Topotecan—ovarian cancer	0.000585	0.00467	CcSEcCtD
Vismodegib—Connective tissue disorder—Vinorelbine—ovarian cancer	0.000584	0.00466	CcSEcCtD
Vismodegib—Muscle spasms—Topotecan—ovarian cancer	0.000582	0.00464	CcSEcCtD
Vismodegib—ABCG2—bone marrow—ovarian cancer	0.000581	0.00858	CbGeAlD
Vismodegib—Hyponatraemia—Paclitaxel—ovarian cancer	0.000581	0.00463	CcSEcCtD
Vismodegib—Pain in extremity—Paclitaxel—ovarian cancer	0.000578	0.00461	CcSEcCtD
Vismodegib—CYP2C8—vagina—ovarian cancer	0.000572	0.00845	CbGeAlD
Vismodegib—Blood alkaline phosphatase increased—Docetaxel—ovarian cancer	0.000563	0.00449	CcSEcCtD
Vismodegib—Ageusia—Epirubicin—ovarian cancer	0.000562	0.00448	CcSEcCtD
Vismodegib—CYP2C9—female reproductive system—ovarian cancer	0.000562	0.0083	CbGeAlD
Vismodegib—ABCG2—female gonad—ovarian cancer	0.00056	0.00827	CbGeAlD
Vismodegib—ABCG2—vagina—ovarian cancer	0.000556	0.00822	CbGeAlD
Vismodegib—Dehydration—Paclitaxel—ovarian cancer	0.000538	0.00429	CcSEcCtD
Vismodegib—Neoplasm malignant—Epirubicin—ovarian cancer	0.000533	0.00425	CcSEcCtD
Vismodegib—Abdominal pain upper—Paclitaxel—ovarian cancer	0.000528	0.00421	CcSEcCtD
Vismodegib—ALB—lymph node—ovarian cancer	0.000527	0.00778	CbGeAlD
Vismodegib—Hypokalaemia—Paclitaxel—ovarian cancer	0.000526	0.0042	CcSEcCtD
Vismodegib—Alopecia—Vinorelbine—ovarian cancer	0.000526	0.00419	CcSEcCtD
Vismodegib—Breast disorder—Paclitaxel—ovarian cancer	0.000523	0.00417	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Paclitaxel—ovarian cancer	0.000521	0.00415	CcSEcCtD
Vismodegib—ABCB1—myometrium—ovarian cancer	0.00052	0.00768	CbGeAlD
Vismodegib—Ageusia—Doxorubicin—ovarian cancer	0.00052	0.00415	CcSEcCtD
Vismodegib—Amenorrhoea—Epirubicin—ovarian cancer	0.000518	0.00413	CcSEcCtD
Vismodegib—Malnutrition—Vinorelbine—ovarian cancer	0.000518	0.00413	CcSEcCtD
Vismodegib—Arthralgia—Topotecan—ovarian cancer	0.000515	0.00411	CcSEcCtD
Vismodegib—Myalgia—Topotecan—ovarian cancer	0.000515	0.00411	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.000512	0.00408	CcSEcCtD
Vismodegib—CYP2C8—testis—ovarian cancer	0.00051	0.00754	CbGeAlD
Vismodegib—Myalgia—Melphalan—ovarian cancer	0.000505	0.00402	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.000501	0.004	CcSEcCtD
Vismodegib—Back pain—Vinorelbine—ovarian cancer	0.000501	0.00399	CcSEcCtD
Vismodegib—ABCB1—embryo—ovarian cancer	0.0005	0.00739	CbGeAlD
Vismodegib—ABCG2—testis—ovarian cancer	0.000496	0.00733	CbGeAlD
Vismodegib—Neoplasm malignant—Doxorubicin—ovarian cancer	0.000493	0.00393	CcSEcCtD
Vismodegib—Hyponatraemia—Docetaxel—ovarian cancer	0.000492	0.00392	CcSEcCtD
Vismodegib—Pain in extremity—Docetaxel—ovarian cancer	0.00049	0.00391	CcSEcCtD
Vismodegib—Dyspepsia—Chlorambucil—ovarian cancer	0.000488	0.00389	CcSEcCtD
Vismodegib—Nervous system disorder—Topotecan—ovarian cancer	0.000484	0.00386	CcSEcCtD
Vismodegib—Decreased appetite—Chlorambucil—ovarian cancer	0.000482	0.00385	CcSEcCtD
Vismodegib—Skin disorder—Topotecan—ovarian cancer	0.00048	0.00383	CcSEcCtD
Vismodegib—Amenorrhoea—Doxorubicin—ovarian cancer	0.00048	0.00382	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.000479	0.00382	CcSEcCtD
Vismodegib—Fatigue—Chlorambucil—ovarian cancer	0.000478	0.00381	CcSEcCtD
Vismodegib—Pain—Chlorambucil—ovarian cancer	0.000474	0.00378	CcSEcCtD
Vismodegib—Skin disorder—Melphalan—ovarian cancer	0.00047	0.00375	CcSEcCtD
Vismodegib—Musculoskeletal pain—Epirubicin—ovarian cancer	0.000461	0.00368	CcSEcCtD
Vismodegib—Dehydration—Docetaxel—ovarian cancer	0.000456	0.00363	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Epirubicin—ovarian cancer	0.000455	0.00363	CcSEcCtD
Vismodegib—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.000454	0.00362	CcSEcCtD
Vismodegib—Weight decreased—Paclitaxel—ovarian cancer	0.000452	0.00361	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.00045	0.00359	CcSEcCtD
Vismodegib—Abdominal pain upper—Docetaxel—ovarian cancer	0.000448	0.00357	CcSEcCtD
Vismodegib—Breast disorder—Docetaxel—ovarian cancer	0.000443	0.00353	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Docetaxel—ovarian cancer	0.000441	0.00352	CcSEcCtD
Vismodegib—Myalgia—Vinorelbine—ovarian cancer	0.000441	0.00351	CcSEcCtD
Vismodegib—Arthralgia—Vinorelbine—ovarian cancer	0.000441	0.00351	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.000441	0.00351	CcSEcCtD
Vismodegib—Abdominal pain—Chlorambucil—ovarian cancer	0.000439	0.0035	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000438	0.00349	CcSEcCtD
Vismodegib—Dyspepsia—Topotecan—ovarian cancer	0.000435	0.00347	CcSEcCtD
Vismodegib—Blood urea increased—Epirubicin—ovarian cancer	0.00043	0.00343	CcSEcCtD
Vismodegib—Decreased appetite—Topotecan—ovarian cancer	0.000429	0.00342	CcSEcCtD
Vismodegib—CYP3A4—female reproductive system—ovarian cancer	0.000428	0.00633	CbGeAlD
Vismodegib—Musculoskeletal pain—Doxorubicin—ovarian cancer	0.000427	0.0034	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000426	0.0034	CcSEcCtD
Vismodegib—Fatigue—Topotecan—ovarian cancer	0.000426	0.0034	CcSEcCtD
Vismodegib—Dyspepsia—Melphalan—ovarian cancer	0.000426	0.00339	CcSEcCtD
Vismodegib—Constipation—Topotecan—ovarian cancer	0.000422	0.00337	CcSEcCtD
Vismodegib—Pain—Topotecan—ovarian cancer	0.000422	0.00337	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Doxorubicin—ovarian cancer	0.000421	0.00336	CcSEcCtD
Vismodegib—Decreased appetite—Melphalan—ovarian cancer	0.00042	0.00335	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000418	0.00333	CcSEcCtD
Vismodegib—Fatigue—Melphalan—ovarian cancer	0.000417	0.00332	CcSEcCtD
Vismodegib—Nervous system disorder—Vinorelbine—ovarian cancer	0.000414	0.0033	CcSEcCtD
Vismodegib—Pain—Melphalan—ovarian cancer	0.000414	0.0033	CcSEcCtD
Vismodegib—Skin disorder—Vinorelbine—ovarian cancer	0.00041	0.00327	CcSEcCtD
Vismodegib—ABCB1—epithelium—ovarian cancer	0.000408	0.00603	CbGeAlD
Vismodegib—ABCB1—uterine cervix—ovarian cancer	0.000405	0.00598	CbGeAlD
Vismodegib—Gastrointestinal pain—Topotecan—ovarian cancer	0.000404	0.00322	CcSEcCtD
Vismodegib—Asthenia—Chlorambucil—ovarian cancer	0.000398	0.00317	CcSEcCtD
Vismodegib—Blood urea increased—Doxorubicin—ovarian cancer	0.000398	0.00317	CcSEcCtD
Vismodegib—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000393	0.00313	CcSEcCtD
Vismodegib—Pruritus—Chlorambucil—ovarian cancer	0.000393	0.00313	CcSEcCtD
Vismodegib—Abdominal pain—Topotecan—ovarian cancer	0.00039	0.00311	CcSEcCtD
Vismodegib—ABCB1—decidua—ovarian cancer	0.000386	0.0057	CbGeAlD
Vismodegib—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000385	0.00307	CcSEcCtD
Vismodegib—Weight decreased—Docetaxel—ovarian cancer	0.000383	0.00306	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Epirubicin—ovarian cancer	0.00038	0.00303	CcSEcCtD
Vismodegib—Diarrhoea—Chlorambucil—ovarian cancer	0.00038	0.00303	CcSEcCtD
Vismodegib—Decreased appetite—Vinorelbine—ovarian cancer	0.000367	0.00293	CcSEcCtD
Vismodegib—ABCB1—endometrium—ovarian cancer	0.000366	0.00541	CbGeAlD
Vismodegib—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000365	0.00291	CcSEcCtD
Vismodegib—Fatigue—Vinorelbine—ovarian cancer	0.000364	0.0029	CcSEcCtD
Vismodegib—Constipation—Vinorelbine—ovarian cancer	0.000361	0.00288	CcSEcCtD
Vismodegib—Pain—Vinorelbine—ovarian cancer	0.000361	0.00288	CcSEcCtD
Vismodegib—ABCG2—lymph node—ovarian cancer	0.00036	0.00532	CbGeAlD
Vismodegib—Asthenia—Topotecan—ovarian cancer	0.000354	0.00283	CcSEcCtD
Vismodegib—Alopecia—Paclitaxel—ovarian cancer	0.000353	0.00282	CcSEcCtD
Vismodegib—Vomiting—Chlorambucil—ovarian cancer	0.000353	0.00281	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Doxorubicin—ovarian cancer	0.000352	0.0028	CcSEcCtD
Vismodegib—Pruritus—Topotecan—ovarian cancer	0.000349	0.00279	CcSEcCtD
Vismodegib—Malnutrition—Paclitaxel—ovarian cancer	0.000348	0.00278	CcSEcCtD
Vismodegib—Asthenia—Melphalan—ovarian cancer	0.000347	0.00277	CcSEcCtD
Vismodegib—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000346	0.00275	CcSEcCtD
Vismodegib—Pruritus—Melphalan—ovarian cancer	0.000342	0.00273	CcSEcCtD
Vismodegib—Dysgeusia—Paclitaxel—ovarian cancer	0.000341	0.00272	CcSEcCtD
Vismodegib—ABCB1—gonad—ovarian cancer	0.00034	0.00502	CbGeAlD
Vismodegib—Diarrhoea—Topotecan—ovarian cancer	0.000338	0.00269	CcSEcCtD
Vismodegib—ABCB1—uterus—ovarian cancer	0.000337	0.00498	CbGeAlD
Vismodegib—Back pain—Paclitaxel—ovarian cancer	0.000337	0.00269	CcSEcCtD
Vismodegib—Muscle spasms—Paclitaxel—ovarian cancer	0.000335	0.00267	CcSEcCtD
Vismodegib—Abdominal pain—Vinorelbine—ovarian cancer	0.000334	0.00266	CcSEcCtD
Vismodegib—Connective tissue disorder—Docetaxel—ovarian cancer	0.000333	0.00266	CcSEcCtD
Vismodegib—Hyponatraemia—Epirubicin—ovarian cancer	0.000332	0.00265	CcSEcCtD
Vismodegib—Diarrhoea—Melphalan—ovarian cancer	0.000331	0.00264	CcSEcCtD
Vismodegib—Pain in extremity—Epirubicin—ovarian cancer	0.000331	0.00264	CcSEcCtD
Vismodegib—Nausea—Chlorambucil—ovarian cancer	0.00033	0.00263	CcSEcCtD
Vismodegib—Vomiting—Topotecan—ovarian cancer	0.000314	0.0025	CcSEcCtD
Vismodegib—Rash—Topotecan—ovarian cancer	0.000311	0.00248	CcSEcCtD
Vismodegib—Dermatitis—Topotecan—ovarian cancer	0.000311	0.00248	CcSEcCtD
Vismodegib—Vomiting—Melphalan—ovarian cancer	0.000308	0.00245	CcSEcCtD
Vismodegib—Dehydration—Epirubicin—ovarian cancer	0.000307	0.00245	CcSEcCtD
Vismodegib—Hyponatraemia—Doxorubicin—ovarian cancer	0.000307	0.00245	CcSEcCtD
Vismodegib—Pain in extremity—Doxorubicin—ovarian cancer	0.000306	0.00244	CcSEcCtD
Vismodegib—Rash—Melphalan—ovarian cancer	0.000305	0.00243	CcSEcCtD
Vismodegib—Dermatitis—Melphalan—ovarian cancer	0.000305	0.00243	CcSEcCtD
Vismodegib—ABCB1—female reproductive system—ovarian cancer	0.000303	0.00448	CbGeAlD
Vismodegib—Asthenia—Vinorelbine—ovarian cancer	0.000303	0.00242	CcSEcCtD
Vismodegib—Abdominal pain upper—Epirubicin—ovarian cancer	0.000302	0.00241	CcSEcCtD
Vismodegib—Hypokalaemia—Epirubicin—ovarian cancer	0.000301	0.0024	CcSEcCtD
Vismodegib—Alopecia—Docetaxel—ovarian cancer	0.0003	0.00239	CcSEcCtD
Vismodegib—Pruritus—Vinorelbine—ovarian cancer	0.000299	0.00238	CcSEcCtD
Vismodegib—Breast disorder—Epirubicin—ovarian cancer	0.000299	0.00238	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000298	0.00237	CcSEcCtD
Vismodegib—Arthralgia—Paclitaxel—ovarian cancer	0.000296	0.00236	CcSEcCtD
Vismodegib—Myalgia—Paclitaxel—ovarian cancer	0.000296	0.00236	CcSEcCtD
Vismodegib—Malnutrition—Docetaxel—ovarian cancer	0.000295	0.00235	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000294	0.00235	CcSEcCtD
Vismodegib—Nausea—Topotecan—ovarian cancer	0.000293	0.00234	CcSEcCtD
Vismodegib—Diarrhoea—Vinorelbine—ovarian cancer	0.000289	0.00231	CcSEcCtD
Vismodegib—Dysgeusia—Docetaxel—ovarian cancer	0.000289	0.0023	CcSEcCtD
Vismodegib—Nausea—Melphalan—ovarian cancer	0.000287	0.00229	CcSEcCtD
Vismodegib—ABCB1—bone marrow—ovarian cancer	0.000286	0.00423	CbGeAlD
Vismodegib—Back pain—Docetaxel—ovarian cancer	0.000286	0.00228	CcSEcCtD
Vismodegib—Dehydration—Doxorubicin—ovarian cancer	0.000284	0.00227	CcSEcCtD
Vismodegib—Muscle spasms—Docetaxel—ovarian cancer	0.000284	0.00226	CcSEcCtD
Vismodegib—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000279	0.00223	CcSEcCtD
Vismodegib—Nervous system disorder—Paclitaxel—ovarian cancer	0.000279	0.00222	CcSEcCtD
Vismodegib—Hypokalaemia—Doxorubicin—ovarian cancer	0.000278	0.00222	CcSEcCtD
Vismodegib—Breast disorder—Doxorubicin—ovarian cancer	0.000276	0.0022	CcSEcCtD
Vismodegib—Skin disorder—Paclitaxel—ovarian cancer	0.000276	0.0022	CcSEcCtD
Vismodegib—ABCB1—female gonad—ovarian cancer	0.000276	0.00408	CbGeAlD
Vismodegib—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000275	0.0022	CcSEcCtD
Vismodegib—ABCB1—vagina—ovarian cancer	0.000274	0.00405	CbGeAlD
Vismodegib—Vomiting—Vinorelbine—ovarian cancer	0.000269	0.00214	CcSEcCtD
Vismodegib—Sorafenib—ABCB1—ovarian cancer	0.000267	0.296	CrCbGaD
Vismodegib—Rash—Vinorelbine—ovarian cancer	0.000266	0.00212	CcSEcCtD
Vismodegib—Dermatitis—Vinorelbine—ovarian cancer	0.000266	0.00212	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000259	0.00206	CcSEcCtD
Vismodegib—Weight decreased—Epirubicin—ovarian cancer	0.000258	0.00206	CcSEcCtD
Vismodegib—Arthralgia—Docetaxel—ovarian cancer	0.000251	0.002	CcSEcCtD
Vismodegib—Myalgia—Docetaxel—ovarian cancer	0.000251	0.002	CcSEcCtD
Vismodegib—Nausea—Vinorelbine—ovarian cancer	0.000251	0.002	CcSEcCtD
Vismodegib—Dyspepsia—Paclitaxel—ovarian cancer	0.00025	0.00199	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00025	0.00199	CcSEcCtD
Vismodegib—Decreased appetite—Paclitaxel—ovarian cancer	0.000247	0.00197	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000245	0.00196	CcSEcCtD
Vismodegib—Fatigue—Paclitaxel—ovarian cancer	0.000245	0.00195	CcSEcCtD
Vismodegib—ABCB1—testis—ovarian cancer	0.000245	0.00362	CbGeAlD
Vismodegib—Pain—Paclitaxel—ovarian cancer	0.000243	0.00194	CcSEcCtD
Vismodegib—Constipation—Paclitaxel—ovarian cancer	0.000243	0.00194	CcSEcCtD
Vismodegib—Weight decreased—Doxorubicin—ovarian cancer	0.000239	0.00191	CcSEcCtD
Vismodegib—Nervous system disorder—Docetaxel—ovarian cancer	0.000236	0.00188	CcSEcCtD
Vismodegib—Skin disorder—Docetaxel—ovarian cancer	0.000234	0.00187	CcSEcCtD
Vismodegib—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000232	0.00185	CcSEcCtD
Vismodegib—Connective tissue disorder—Epirubicin—ovarian cancer	0.000225	0.00179	CcSEcCtD
Vismodegib—Abdominal pain—Paclitaxel—ovarian cancer	0.000225	0.00179	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000219	0.00175	CcSEcCtD
Vismodegib—Dyspepsia—Docetaxel—ovarian cancer	0.000212	0.00169	CcSEcCtD
Vismodegib—Decreased appetite—Docetaxel—ovarian cancer	0.000209	0.00167	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000208	0.00166	CcSEcCtD
Vismodegib—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000208	0.00166	CcSEcCtD
Vismodegib—Fatigue—Docetaxel—ovarian cancer	0.000208	0.00166	CcSEcCtD
Vismodegib—Constipation—Docetaxel—ovarian cancer	0.000206	0.00164	CcSEcCtD
Vismodegib—Pain—Docetaxel—ovarian cancer	0.000206	0.00164	CcSEcCtD
Vismodegib—Asthenia—Paclitaxel—ovarian cancer	0.000204	0.00163	CcSEcCtD
Vismodegib—Alopecia—Epirubicin—ovarian cancer	0.000202	0.00161	CcSEcCtD
Vismodegib—Pruritus—Paclitaxel—ovarian cancer	0.000201	0.0016	CcSEcCtD
Vismodegib—Malnutrition—Epirubicin—ovarian cancer	0.000199	0.00159	CcSEcCtD
Vismodegib—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000197	0.00157	CcSEcCtD
Vismodegib—Dysgeusia—Epirubicin—ovarian cancer	0.000195	0.00155	CcSEcCtD
Vismodegib—Diarrhoea—Paclitaxel—ovarian cancer	0.000194	0.00155	CcSEcCtD
Vismodegib—Back pain—Epirubicin—ovarian cancer	0.000193	0.00154	CcSEcCtD
Vismodegib—Muscle spasms—Epirubicin—ovarian cancer	0.000191	0.00153	CcSEcCtD
Vismodegib—Abdominal pain—Docetaxel—ovarian cancer	0.00019	0.00152	CcSEcCtD
Vismodegib—Alopecia—Doxorubicin—ovarian cancer	0.000187	0.00149	CcSEcCtD
Vismodegib—Malnutrition—Doxorubicin—ovarian cancer	0.000184	0.00147	CcSEcCtD
Vismodegib—Vomiting—Paclitaxel—ovarian cancer	0.000181	0.00144	CcSEcCtD
Vismodegib—Dysgeusia—Doxorubicin—ovarian cancer	0.00018	0.00144	CcSEcCtD
Vismodegib—Rash—Paclitaxel—ovarian cancer	0.000179	0.00143	CcSEcCtD
Vismodegib—Dermatitis—Paclitaxel—ovarian cancer	0.000179	0.00143	CcSEcCtD
Vismodegib—Back pain—Doxorubicin—ovarian cancer	0.000178	0.00142	CcSEcCtD
Vismodegib—ABCB1—lymph node—ovarian cancer	0.000177	0.00262	CbGeAlD
Vismodegib—Muscle spasms—Doxorubicin—ovarian cancer	0.000177	0.00141	CcSEcCtD
Vismodegib—Asthenia—Docetaxel—ovarian cancer	0.000173	0.00138	CcSEcCtD
Vismodegib—Pruritus—Docetaxel—ovarian cancer	0.00017	0.00136	CcSEcCtD
Vismodegib—Arthralgia—Epirubicin—ovarian cancer	0.000169	0.00135	CcSEcCtD
Vismodegib—Myalgia—Epirubicin—ovarian cancer	0.000169	0.00135	CcSEcCtD
Vismodegib—Nausea—Paclitaxel—ovarian cancer	0.000169	0.00135	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000168	0.00134	CcSEcCtD
Vismodegib—Diarrhoea—Docetaxel—ovarian cancer	0.000165	0.00131	CcSEcCtD
Vismodegib—Nervous system disorder—Epirubicin—ovarian cancer	0.000159	0.00127	CcSEcCtD
Vismodegib—Skin disorder—Epirubicin—ovarian cancer	0.000158	0.00126	CcSEcCtD
Vismodegib—Arthralgia—Doxorubicin—ovarian cancer	0.000157	0.00125	CcSEcCtD
Vismodegib—Myalgia—Doxorubicin—ovarian cancer	0.000157	0.00125	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000156	0.00124	CcSEcCtD
Vismodegib—Vomiting—Docetaxel—ovarian cancer	0.000153	0.00122	CcSEcCtD
Vismodegib—Rash—Docetaxel—ovarian cancer	0.000152	0.00121	CcSEcCtD
Vismodegib—Dermatitis—Docetaxel—ovarian cancer	0.000152	0.00121	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000148	0.00118	CcSEcCtD
Vismodegib—Nervous system disorder—Doxorubicin—ovarian cancer	0.000147	0.00118	CcSEcCtD
Vismodegib—Skin disorder—Doxorubicin—ovarian cancer	0.000146	0.00116	CcSEcCtD
Vismodegib—Nausea—Docetaxel—ovarian cancer	0.000143	0.00114	CcSEcCtD
Vismodegib—Dyspepsia—Epirubicin—ovarian cancer	0.000143	0.00114	CcSEcCtD
Vismodegib—Decreased appetite—Epirubicin—ovarian cancer	0.000141	0.00113	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.00014	0.00112	CcSEcCtD
Vismodegib—Fatigue—Epirubicin—ovarian cancer	0.00014	0.00112	CcSEcCtD
Vismodegib—Constipation—Epirubicin—ovarian cancer	0.000139	0.00111	CcSEcCtD
Vismodegib—Pain—Epirubicin—ovarian cancer	0.000139	0.00111	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000137	0.00109	CcSEcCtD
Vismodegib—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000133	0.00106	CcSEcCtD
Vismodegib—Dyspepsia—Doxorubicin—ovarian cancer	0.000132	0.00106	CcSEcCtD
Vismodegib—Decreased appetite—Doxorubicin—ovarian cancer	0.000131	0.00104	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.00013	0.00103	CcSEcCtD
Vismodegib—Fatigue—Doxorubicin—ovarian cancer	0.00013	0.00103	CcSEcCtD
Vismodegib—Pain—Doxorubicin—ovarian cancer	0.000129	0.00103	CcSEcCtD
Vismodegib—Constipation—Doxorubicin—ovarian cancer	0.000129	0.00103	CcSEcCtD
Vismodegib—Abdominal pain—Epirubicin—ovarian cancer	0.000128	0.00102	CcSEcCtD
Vismodegib—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000123	0.00098	CcSEcCtD
Vismodegib—Abdominal pain—Doxorubicin—ovarian cancer	0.000119	0.000948	CcSEcCtD
Vismodegib—Asthenia—Epirubicin—ovarian cancer	0.000117	0.00093	CcSEcCtD
Vismodegib—Pruritus—Epirubicin—ovarian cancer	0.000115	0.000917	CcSEcCtD
Vismodegib—Diarrhoea—Epirubicin—ovarian cancer	0.000111	0.000886	CcSEcCtD
Vismodegib—Asthenia—Doxorubicin—ovarian cancer	0.000108	0.00086	CcSEcCtD
Vismodegib—Pruritus—Doxorubicin—ovarian cancer	0.000106	0.000848	CcSEcCtD
Vismodegib—Vomiting—Epirubicin—ovarian cancer	0.000103	0.000824	CcSEcCtD
Vismodegib—Diarrhoea—Doxorubicin—ovarian cancer	0.000103	0.00082	CcSEcCtD
Vismodegib—Rash—Epirubicin—ovarian cancer	0.000102	0.000817	CcSEcCtD
Vismodegib—Dermatitis—Epirubicin—ovarian cancer	0.000102	0.000816	CcSEcCtD
Vismodegib—Nausea—Epirubicin—ovarian cancer	9.65e-05	0.00077	CcSEcCtD
Vismodegib—Vomiting—Doxorubicin—ovarian cancer	9.56e-05	0.000762	CcSEcCtD
Vismodegib—Rash—Doxorubicin—ovarian cancer	9.48e-05	0.000756	CcSEcCtD
Vismodegib—Dermatitis—Doxorubicin—ovarian cancer	9.47e-05	0.000755	CcSEcCtD
Vismodegib—Nausea—Doxorubicin—ovarian cancer	8.93e-05	0.000712	CcSEcCtD
Vismodegib—SMO—Signaling Pathways—PIK3CB—ovarian cancer	2.88e-05	0.000354	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MTOR—ovarian cancer	2.88e-05	0.000354	CbGpPWpGaD
Vismodegib—ALB—Selenium Micronutrient Network—IL6—ovarian cancer	2.88e-05	0.000354	CbGpPWpGaD
Vismodegib—SHH—Disease—KRAS—ovarian cancer	2.88e-05	0.000354	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CDKN1B—ovarian cancer	2.85e-05	0.000351	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CASP3—ovarian cancer	2.8e-05	0.000344	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—IL2—ovarian cancer	2.79e-05	0.000343	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—IL6—ovarian cancer	2.78e-05	0.000342	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CXCL8—ovarian cancer	2.77e-05	0.00034	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—HRAS—ovarian cancer	2.75e-05	0.000338	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CCND1—ovarian cancer	2.72e-05	0.000335	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CYTB—ovarian cancer	2.71e-05	0.000333	CbGpPWpGaD
Vismodegib—ALB—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.71e-05	0.000333	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CDKN1B—ovarian cancer	2.71e-05	0.000333	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CYTB—ovarian cancer	2.7e-05	0.000332	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CTNNB1—ovarian cancer	2.7e-05	0.000331	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.65e-05	0.000326	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CASP3—ovarian cancer	2.65e-05	0.000326	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—IL2—ovarian cancer	2.65e-05	0.000325	CbGpPWpGaD
Vismodegib—SHH—Disease—PIK3CA—ovarian cancer	2.65e-05	0.000325	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—MMP9—ovarian cancer	2.64e-05	0.000325	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.64e-05	0.000324	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—IL6—ovarian cancer	2.63e-05	0.000324	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PTEN—ovarian cancer	2.63e-05	0.000323	CbGpPWpGaD
Vismodegib—ALB—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.62e-05	0.000321	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.6e-05	0.000319	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—SOD1—ovarian cancer	2.58e-05	0.000317	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CCND1—ovarian cancer	2.58e-05	0.000317	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PPP2R1A—ovarian cancer	2.57e-05	0.000316	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—AKT1—ovarian cancer	2.56e-05	0.000315	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—YAP1—ovarian cancer	2.56e-05	0.000315	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CTNNB1—ovarian cancer	2.56e-05	0.000314	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—PIK3CB—ovarian cancer	2.56e-05	0.000314	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	2.55e-05	0.000313	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MMP9—ovarian cancer	2.51e-05	0.000308	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PTEN—ovarian cancer	2.49e-05	0.000306	CbGpPWpGaD
Vismodegib—SHH—Disease—HRAS—ovarian cancer	2.45e-05	0.000301	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—AKT1—ovarian cancer	2.43e-05	0.000299	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CYTB—ovarian cancer	2.42e-05	0.000298	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—VEGFA—ovarian cancer	2.37e-05	0.000292	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.37e-05	0.000292	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—BRIP1—ovarian cancer	2.37e-05	0.000291	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PPP1CC—ovarian cancer	2.37e-05	0.000291	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.37e-05	0.000291	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.37e-05	0.000291	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CYTB—ovarian cancer	2.36e-05	0.00029	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	2.36e-05	0.00029	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PPP1CC—ovarian cancer	2.36e-05	0.00029	CbGpPWpGaD
Vismodegib—ALB—Metabolism—BRIP1—ovarian cancer	2.36e-05	0.00029	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—STAT3—ovarian cancer	2.35e-05	0.000289	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—IL2—ovarian cancer	2.35e-05	0.000288	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—NRAS—ovarian cancer	2.34e-05	0.000288	CbGpPWpGaD
Vismodegib—SHH—Disease—IL6—ovarian cancer	2.34e-05	0.000288	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	2.31e-05	0.000284	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.29e-05	0.000282	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NME2—ovarian cancer	2.26e-05	0.000278	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	2.25e-05	0.000277	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—VEGFA—ovarian cancer	2.25e-05	0.000277	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—MAPK3—ovarian cancer	2.25e-05	0.000276	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	2.23e-05	0.000274	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—STAT3—ovarian cancer	2.23e-05	0.000274	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—NRAS—ovarian cancer	2.22e-05	0.000273	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CYTB—ovarian cancer	2.21e-05	0.000271	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—MYC—ovarian cancer	2.18e-05	0.000268	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	2.17e-05	0.000267	CbGpPWpGaD
Vismodegib—SHH—Disease—AKT1—ovarian cancer	2.16e-05	0.000266	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.16e-05	0.000265	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—MAPK1—ovarian cancer	2.14e-05	0.000263	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—EGFR—ovarian cancer	2.14e-05	0.000263	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MAPK3—ovarian cancer	2.13e-05	0.000262	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PPP1CC—ovarian cancer	2.12e-05	0.00026	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—BRIP1—ovarian cancer	2.12e-05	0.00026	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—FASN—ovarian cancer	2.09e-05	0.000257	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MYC—ovarian cancer	2.07e-05	0.000254	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PPP1CC—ovarian cancer	2.07e-05	0.000254	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—BRIP1—ovarian cancer	2.07e-05	0.000254	CbGpPWpGaD
Vismodegib—ALB—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.06e-05	0.000254	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—SLC5A5—ovarian cancer	2.06e-05	0.000253	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MAPK1—ovarian cancer	2.03e-05	0.000249	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—EGFR—ovarian cancer	2.02e-05	0.000249	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—KRAS—ovarian cancer	2.02e-05	0.000248	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	1.99e-05	0.000245	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—SLC2A1—ovarian cancer	1.98e-05	0.000244	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	1.96e-05	0.000241	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PPP1CC—ovarian cancer	1.93e-05	0.000237	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—BRIP1—ovarian cancer	1.93e-05	0.000237	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—KRAS—ovarian cancer	1.91e-05	0.000235	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CYP1B1—ovarian cancer	1.9e-05	0.000234	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—CAV1—ovarian cancer	1.89e-05	0.000232	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	1.89e-05	0.000232	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	1.86e-05	0.000228	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PIK3CA—ovarian cancer	1.85e-05	0.000228	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	1.81e-05	0.000222	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	1.8e-05	0.000221	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TP53—ovarian cancer	1.79e-05	0.00022	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	1.77e-05	0.000217	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	1.77e-05	0.000217	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PIK3CA—ovarian cancer	1.76e-05	0.000216	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.73e-05	0.000212	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CG—ovarian cancer	1.72e-05	0.000211	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.72e-05	0.000211	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—HRAS—ovarian cancer	1.72e-05	0.000211	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TP53—ovarian cancer	1.7e-05	0.000209	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PPP2R1A—ovarian cancer	1.69e-05	0.000207	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.67e-05	0.000205	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—IL6—ovarian cancer	1.64e-05	0.000202	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—HRAS—ovarian cancer	1.63e-05	0.0002	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—YAP1—ovarian cancer	1.59e-05	0.000195	CbGpPWpGaD
Vismodegib—ALB—Metabolism—YAP1—ovarian cancer	1.58e-05	0.000194	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.57e-05	0.000193	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—ABCB1—ovarian cancer	1.57e-05	0.000193	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.57e-05	0.000192	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	1.56e-05	0.000191	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—IL6—ovarian cancer	1.56e-05	0.000191	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.54e-05	0.00019	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—TYMS—ovarian cancer	1.54e-05	0.000189	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.53e-05	0.000189	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—AKT1—ovarian cancer	1.51e-05	0.000186	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CD—ovarian cancer	1.51e-05	0.000186	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.48e-05	0.000182	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYTB—ovarian cancer	1.46e-05	0.000179	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—AKT1—ovarian cancer	1.44e-05	0.000176	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—YAP1—ovarian cancer	1.42e-05	0.000174	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.41e-05	0.000173	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.41e-05	0.000173	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—YAP1—ovarian cancer	1.39e-05	0.00017	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.38e-05	0.00017	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.38e-05	0.000169	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CB—ovarian cancer	1.32e-05	0.000162	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—FASN—ovarian cancer	1.3e-05	0.000159	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—YAP1—ovarian cancer	1.29e-05	0.000159	CbGpPWpGaD
Vismodegib—ALB—Metabolism—FASN—ovarian cancer	1.29e-05	0.000158	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.28e-05	0.000157	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—SLC5A5—ovarian cancer	1.28e-05	0.000157	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.27e-05	0.000156	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.27e-05	0.000156	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	1.27e-05	0.000156	CbGpPWpGaD
Vismodegib—ALB—Metabolism—SLC5A5—ovarian cancer	1.27e-05	0.000156	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.25e-05	0.000154	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CAV1—ovarian cancer	1.24e-05	0.000152	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.24e-05	0.000152	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—SLC2A1—ovarian cancer	1.23e-05	0.000151	CbGpPWpGaD
Vismodegib—ALB—Metabolism—SLC2A1—ovarian cancer	1.22e-05	0.000151	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—IL2—ovarian cancer	1.21e-05	0.000149	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.21e-05	0.000148	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.2e-05	0.000147	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CYP1B1—ovarian cancer	1.18e-05	0.000145	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CYP1B1—ovarian cancer	1.17e-05	0.000144	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—FASN—ovarian cancer	1.16e-05	0.000142	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—SLC5A5—ovarian cancer	1.14e-05	0.00014	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—FASN—ovarian cancer	1.13e-05	0.000139	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CG—ovarian cancer	1.13e-05	0.000139	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.13e-05	0.000138	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—SLC5A5—ovarian cancer	1.11e-05	0.000137	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—SLC2A1—ovarian cancer	1.1e-05	0.000135	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.08e-05	0.000132	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—SLC2A1—ovarian cancer	1.07e-05	0.000132	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—FASN—ovarian cancer	1.06e-05	0.00013	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CYP1B1—ovarian cancer	1.05e-05	0.00013	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	1.05e-05	0.000129	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.04e-05	0.000128	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PPP2R1A—ovarian cancer	1.04e-05	0.000128	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—SLC5A5—ovarian cancer	1.04e-05	0.000128	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.04e-05	0.000127	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CYP1B1—ovarian cancer	1.03e-05	0.000126	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—VEGFA—ovarian cancer	1.03e-05	0.000126	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—NRAS—ovarian cancer	1.02e-05	0.000125	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—SLC2A1—ovarian cancer	1e-05	0.000123	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CD—ovarian cancer	9.93e-06	0.000122	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	9.82e-06	0.000121	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—MAPK3—ovarian cancer	9.73e-06	0.00012	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ABCB1—ovarian cancer	9.73e-06	0.00012	CbGpPWpGaD
Vismodegib—ALB—Metabolism—ABCB1—ovarian cancer	9.67e-06	0.000119	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CYP1B1—ovarian cancer	9.61e-06	0.000118	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—TYMS—ovarian cancer	9.55e-06	0.000117	CbGpPWpGaD
Vismodegib—ALB—Metabolism—TYMS—ovarian cancer	9.5e-06	0.000117	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	9.35e-06	0.000115	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.3e-06	0.000114	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—MAPK1—ovarian cancer	9.25e-06	0.000114	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PPP2R1A—ovarian cancer	9.12e-06	0.000112	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—KRAS—ovarian cancer	8.74e-06	0.000107	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ABCB1—ovarian cancer	8.68e-06	0.000107	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CB—ovarian cancer	8.66e-06	0.000106	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—YAP1—ovarian cancer	8.54e-06	0.000105	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—TYMS—ovarian cancer	8.53e-06	0.000105	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	8.52e-06	0.000105	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	8.48e-06	0.000104	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—TYMS—ovarian cancer	8.32e-06	0.000102	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CA—ovarian cancer	8.03e-06	9.87e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ABCB1—ovarian cancer	7.92e-06	9.73e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—TYMS—ovarian cancer	7.77e-06	9.55e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TP53—ovarian cancer	7.77e-06	9.55e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CAV1—ovarian cancer	7.7e-06	9.46e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CAV1—ovarian cancer	7.65e-06	9.4e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PTEN—ovarian cancer	7.48e-06	9.19e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—HRAS—ovarian cancer	7.43e-06	9.13e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.35e-06	9.04e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.31e-06	8.99e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CG—ovarian cancer	7.01e-06	8.62e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CG—ovarian cancer	6.97e-06	8.57e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—FASN—ovarian cancer	6.96e-06	8.55e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CAV1—ovarian cancer	6.87e-06	8.44e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	6.85e-06	8.41e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CAV1—ovarian cancer	6.71e-06	8.24e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	6.61e-06	8.13e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.56e-06	8.07e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—AKT1—ovarian cancer	6.56e-06	8.06e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	6.34e-06	7.79e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CAV1—ovarian cancer	6.26e-06	7.7e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CG—ovarian cancer	6.26e-06	7.69e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CD—ovarian cancer	6.16e-06	7.57e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CD—ovarian cancer	6.13e-06	7.53e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CG—ovarian cancer	6.11e-06	7.51e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.98e-06	7.35e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CG—ovarian cancer	5.71e-06	7.01e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	5.62e-06	6.91e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CD—ovarian cancer	5.5e-06	6.76e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CB—ovarian cancer	5.37e-06	6.6e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CD—ovarian cancer	5.37e-06	6.6e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CB—ovarian cancer	5.34e-06	6.56e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CA—ovarian cancer	5.28e-06	6.48e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ABCB1—ovarian cancer	5.22e-06	6.42e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—TYMS—ovarian cancer	5.13e-06	6.3e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CD—ovarian cancer	5.02e-06	6.16e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CB—ovarian cancer	4.79e-06	5.89e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CB—ovarian cancer	4.68e-06	5.75e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PTEN—ovarian cancer	4.64e-06	5.7e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PTEN—ovarian cancer	4.62e-06	5.67e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CB—ovarian cancer	4.37e-06	5.37e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—AKT1—ovarian cancer	4.31e-06	5.3e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PTEN—ovarian cancer	4.14e-06	5.09e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CAV1—ovarian cancer	4.13e-06	5.08e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PTEN—ovarian cancer	4.04e-06	4.97e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PTEN—ovarian cancer	3.78e-06	4.64e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.76e-06	4.62e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	3.31e-06	4.07e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CA—ovarian cancer	3.27e-06	4.02e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CA—ovarian cancer	3.26e-06	4e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CA—ovarian cancer	2.92e-06	3.59e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.88e-06	3.54e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.85e-06	3.51e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—AKT1—ovarian cancer	2.68e-06	3.29e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CA—ovarian cancer	2.67e-06	3.28e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—AKT1—ovarian cancer	2.66e-06	3.27e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PTEN—ovarian cancer	2.49e-06	3.06e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—AKT1—ovarian cancer	2.39e-06	2.93e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—AKT1—ovarian cancer	2.33e-06	2.86e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—AKT1—ovarian cancer	2.18e-06	2.68e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.76e-06	2.16e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—AKT1—ovarian cancer	1.44e-06	1.76e-05	CbGpPWpGaD
